Shilpa Medicare ink pact to sell 31 percent stake in Sravathi Advanced Process Technologies for Rs 49.6 crore

Published On 2025-10-28 08:58 GMT | Update On 2025-10-28 08:58 GMT

Karnataka: Shilpa Medicare Limited has announced that it has entered into a Share Purchase Agreement and Shareholders' Agreement with Ash Ingredients Inc. and Varcatalyst LLP to sell 31% of its stake held in Sravathi Advanced Process Technologies Pvt. Ltd. for a total consideration of Rs 49.6 crore, subject to customary closing conditions.

Following the transaction, Shilpa’s shareholding in Sravathi will reduce from 65% to 34%, while the technocrat founders will continue to hold 35%. Ash Ingredients Inc. and Varcatalyst LLP will hold 22% and 9% respectively.

As per the BSE filing, the transaction aims to bring in strategic and financial partners to bolster the business of Sravathi Technologies, a company engaged in advanced differentiated process technologies & research and development.

As part of the agreement, Ash Ingredients Inc. and Varcatalyst LLP have the right to appoint a director each on the Board of Sravathi.

Upon Closing of the transaction, the new agreements will supersede the earlier joint venture agreement dated June 7, 2019, between Shilpa, Technocrats, and Sravathi.

Shilpa Medicare is a global pharmaceutical company specializing in contract development and manufacturing services for small and large molecules. With a strong emphasis on oncology and a growing presence in biologics, the company offers comprehensive solutions from discovery to commercial supply. Shilpa Medicare operates R&D and manufacturing facilities, serving partners across North America, Europe, and Asia.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Shilpa Medicare ink pact to sell 31 percent stake in Sravathi Advanced Process Technologies for Rs 49.6 crore

Similar News

US.FDA nod to updated indication for Winrevair in adults with Pulmonary Arterial Hypertension

Zydus Wellness appoints Manish Lal as Head, Global Demand and Supply Organization

Eli Lilly Omvoh secures USFDA approval as single-injection maintenance regimen in adults with ulcerative colitis

Deepak Arora takes charge of Sanofi India as Managing Director

GSK acquires exclusive rights from Syndivia for antibody drug conjugate in prostate cancer

Pharma Price Row Turns Deadly in Kanpur: Student's Stomach Slashed, Fingers Chopped, Intestines Tied

Emcure Pharma's Wellness Arm Arth Ropes In MS Dhoni to Promote Sleep Gummies Range